Tradestie Institutional Equity Comparison Engine
EDIT vs JBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
JBIO Overall Edge
JBIO Captures Institutional Edge (3โ0 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Jade Biosciences, Inc. Common Stock (JBIO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, EDIT trades at N/M Forward P/E with -167.0% operating margin (+37.4% YoY revenue) versus JBIO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EDIT sits in BREAKDOWN (38th %ile IV; Dealer Gamma Walls on Pro) against JBIO sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
EDIT N/M vs JBIO N/M Fwd P/E
Growth & Margin Winner
JBIO
Op Margin -167.0% vs 0.0% ยท YoY +37.4% vs +0.0%
Momentum & Technical Winner
JBIO
1Y -25.0% vs +58.5% ยท 52W Pos 11% vs 32%
Options & Structure Winner
JBIO
BREAKDOWN (38th %ile IV) vs BREAKDOWN (6th %ile IV)
EDIT
NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap
$336.5M
1M Return
-18.94%
1Y Return
-25.0%
Forward P/E
N/M
Unified AI Score
51.6 / 100
HOLD
Tech 40.0
Fund 54.0
Flow 69.0
Mom 60.0
JBIO
NASDAQ
Jade Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$15.34
-4.96% 1D
Market Cap
$1.0B
1M Return
+13.88%
1Y Return
+58.47%
Forward P/E
N/M
Unified AI Score
38.0 / 100
SELL
Tech 20.0
Fund 41.0
Flow 73.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
EDIT -25.0%
JBIO +58.47%
Spread: +83.47 pp (JBIO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
EDIT TTM Op. Margin: -167.0%
JBIO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EDIT vs JBIO. Trailing 12-month operating profitability (EDIT -167.0% vs JBIO 0.0%) and valuation multiples (EDIT N/M vs JBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EDIT | JBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $336.5M | $1.0B | Larger Scale | JBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +37.4% | +0.0% | Higher Growth | EDIT |
| Operating Margin (TTM) Profitability | -167.0% | 0.0% | Higher Margin | JBIO |
| Net Profit Margin Profitability | -144.9% | 0.0% | Higher Margin | JBIO |
| Return on Equity (ROE) Capital Efficiency | -147.4% | -89.2% | Higher ROE | JBIO |
| 52-Week Range Position Momentum | 11% ($2โ$4) | 32% ($10โ$28) | Stronger Trend | JBIO |
| Beta / 30D Volatility Risk Regime | 2.32ฮฒ ยท 102% Vol | 1.35ฮฒ ยท 60% Vol | Lower Realized Risk | JBIO |
| Unified Institutional Score Composite Signal | 51.6 / 100 (HOLD) | 38.0 / 100 (SELL) | Higher Composite | EDIT |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full EDIT vs JBIO Buy Guide
EDIT
BREAKDOWN
146d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
38th %ile
IV Regime
Balanced (25thโ60th %ile)
JBIO
BREAKDOWN
141d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
6th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither EDIT nor JBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.